Scottish Contract Research Organisation BioOutsource have been acquired by global biopharmaceutical supplier Sartorius Stedim Biotech (SSB) for an undisclosed amount. The takeover strengthens SSB’s service portfolio throughout the drug development pathway, enabling the company to better support their biopharma clients in their drive to fast-track novel drug candidates through the development and clinical test phases.
Welcoming the acquisition, Gerry MacKay, CEO of BioOutsource said “We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services. As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing. We would also like to take this opportunity to thank one of our original shareholders Scottish Investment Bank, the investment arm of Scottish Enterprise, for their continued investment and support over the last 7 years”.
Reinhard Vogt, member of SSB’s Board, commented: “By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them.”
You can read BioOutsource’s full press release on their website.
Follow Evolution Global Talent Attraction on Twitter, Facebook and LinkedIN to keep up-to-date with news and trends from the biotechnology, biosciences, medical device, IT and Intellectual Property industries.
